Subscribe to Get Prostate Cancer News

Hot SHEET 2020

Made possible by charitable contributions from


 - Thank You!


Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Subscribe to get the Hot SHEET (and other prostate cancer news and information) for free via email from Us TOO at

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.

  • Pembrolizumab Shows Limited Activity Against Prostate Cancer
  • When the Going Gets Tough… How to Help Yourself or a Friend
  • Olaparib in Patients with Metastatic Castrate-Resistant Prostate Cancer
  • Impact of Age at Diagnosis of De Novo Metastatic Prostate Cancer
  • Clinical Utility of a Genomic Classifier In Men Undergoing RP
  • Doc Moyad's No Bogus Science Column: "2020—The Year of the Statin & Elvis?!"
  • Variation in the Prescription of Androgen Deprivation Therapy
  • The Role of Hypofractionated Radiotherapy for Localized PCa
  • New Tools May ID Intermediate-Risk PCa Patients Suitable for AS
  • Index of Articles Published in 2019 Us TOO Hot SHEETs
  • Chemo Triumphs in Second Line Metastatic Prostate Cancer
  • Salvage RT First Found Superior for Post-RP PSA Failure
  • Tailored Pelvic PT May Curb Post-RP Incontinence & Pain
  • AS, RP, EBRT or Brachytherapy With or Without ADT
  • Doc Moyad's No Bogus Science Column: "Resistance Training!?"
  • Extended Pelvic Lymph Node Dissection & PCa Outcomes
  • More Veggies No Help in AS
  • Outcomes of Hypofractionated/ Conventionally Fractionated RT
  • Anterior-Dominant PCa Harder to Detect Than Other Locations
  • Impact of MRI & Targeted Biop-sies on Eligibility for Surveillance
  • Implications of Germline Genetic Testing in Prostate Cancer
  • Tumor-Associated Release of Prostatic Cells After Biopsies


  • Lower Out-of-Pocket Costs for Robotic Cancer Surgery
  • More Radium-223 in mCRPC Means More Toxicity
  • Stalling ADT Use in Recurrent PCa
  • Validation of Gallium-68 PSMA PET/CT for Primary PCa Staging
  • Long-Term Follow-Up in Low-Dose-Rate Brachytherapy for PCa
  • Doc Moyad's No Bogus Science: "Lorcaserin Bites the Dust!?"
  • Apalutamide & Overall Survival in Non-Metastatic CRPC
  • Pembrolizumab for Treating Refractory Metastatic CRPC
  • PET Spots Prostate Cancer Metastases Missed on CT, MRI
  • Modest Survival Gains Shown in Newly Diagnosed Metastatic PCa
  • Long-Term Outcomes in Gleason Grades 2 & 3 PCa with AS
  • Guest Column: Staying Sexually Active After PCa Treatment
  • Earlier Cabazitaxel Use in mCRPC
  • FDA Panel Thumbs Down for Cancer Focal Therapy
  • Apalutamide Benefit Sustained in Metastatic Castrate-Sensitive PCa
  • Hypofractionate RT for PCa Stands the Test of Time
  • Enzalutamide, ADT and Salvage RT in High-Risk PSA-Recurrent PCa
  • Robotic-Assisted RP & Persistent Postoperative Opioid Use
  • Doc Moyad's No Bogus Science: "Heart Healthy = Immune Healthy = Prostate Healthy!?"
  • The Cost of Bottling Up Emotions
  • Sunitinib, Docetaxel & Prednisone in Chemo-Naïve Metastatic CRPC
  • Less Frequent Prostate Cancer Screening a Good Idea
  • Guest Column: Goodbye Poke and Hope!
  • HSD3B1 Genotype Tied to Prostate Cancer Outcomes

  • Defining a Role for Immunotherapy in mCRPC
  • Veteran’s Health Bill Promotes Comprehensive PCa Care Program
  • Prostatectomy of Mixed Mortality Benefit in Men with Prostate Cancer
  • Long-Term Unmet Supportive Care Needs of Prostate Cancer Survivors
  • AS vs. Immediate Treatment – Financial Incentives for Urologists
  • Doc Moyad’s No Bogus Science: “Are Low-Carb Diets Groovy Now!?”
  • Combined Biopsy Strategy Improved Prostate Cancer Diagnosis
  • 177Lu-PSMA Radionuclide Treatment in Men with Metastatic CRPC
  • PSMA PET/CT Better Detects Prostate Cancer Spread
  • Genomic Prostate Score Does Not Improve Risk Assessment
  • Its a Bust Adding Immunotherapy No Benefit in mCRPC
  • Time to Reassess Risks of Active Surveillance in Prostate Cancer?
  • Too Much RT Still Being Used for Bone Metastases
  • Randomized Trial of Conventional vs. Hypofractionated IMRT
  • Shared Decision Making & PSA-Based PCa Screening
  • Genomic Prostate Score (GPS) Results in the Canary AS Study
  • Doc Moyad's No Bogus Science Column: "Intrusive Thoughts?"
  • RP Without Pelvic Lymph Node Dissection is Widely Practiced
  • Guest Column: Options for Urinary Incontinence After PCa Treatment
  • Darolutamide & ADT vs. ADT Alone in Non-Metastatic CRPC
  • Prostate SBRT Shows Positive Outcomes in Treatment of Low and Intermediate-Risk Disease